RARE vs UNH

Ultragenyx (RARE) maintains its compelling high-risk, high-reward profile, scoring 79/100 for 10x potential within 3-5 years. The company has made significant strides in advancing its gene therapy pipeline, with the FDA accepting the BLA resubmission for UX111, positive Phase 3 results for DTX301, and IND clearance for UX016. These milestones directly validate the strategic vision for addressing s...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...